Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HepTcell in inactive chronic hepatitis B
NCT04684914Phase 2Terminated
- Sponsor
- Altimmune, Inc.
- Start
- Dec 2020
- Primary completion
- Mar 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing HepTcell with Placebo (2 arms). Primary endpoint: Proportion of Patients Achieving Virologic Responses at 24 weeks. Started Dec 2020; status: terminated.
02
Drugs
HepTcell
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04684914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684914.